Alnylam Reimbursement Win And Trial Progress Versus Current Valuation Signals [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
Alnylam Pharmaceuticals (NasdaqGS:ALNY) received a positive recommendation from Canada's Drug Agency for public reimbursement of AMVUTTRA to treat cardiomyopathy in adult patients with transthyretin mediated amyloidosis, backed by results from the HELIOS B Phase 3 study. The company also completed the KARDIA 3 Phase 2 trial of zilebesiran as an add on therapy for resistant hypertension, advancing its cardiovascular pipeline. Alnylam focuses on RNA interference based therapies, with AMVUTTRA already positioned as a treatment option in transthyretin mediated amyloidosis. The Canadian reimbursement recommendation adds another potential market for AMVUTTRA, and zilebesiran extends the company's reach into cardiovascular disease through an add on approach in resistant hypertension. For investors tracking NasdaqGS:ALNY, these updates highlight new regulatory and clinical milestones that may influence how the product portfolio evolves across different treatment areas. As reimbursement
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments [Yahoo! Finance]Yahoo! Finance
- Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development [Yahoo! Finance]Yahoo! Finance
- Alnylam's research pact worth up to $1.1B sends Tenaya higher [Seeking Alpha]Seeking Alpha
- Alnylam Pharmaceuticals Touts AMVUTTRA Momentum, Teases Key Pipeline Readouts at TD Cowen Conf. [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals, Inc. (ALNY) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- ALNY's page on the SEC website